Literature DB >> 26676826

Predictors and characteristics of seizures in survivors of progressive multifocal leukoencephalopathy.

Dhanashri P Miskin1, Susan T Herman2, Long H Ngo3, Igor J Koralnik4.   

Abstract

This study aims to determine the risk factors for epileptogenesis and characteristics of seizures in patients with progressive multifocal leukoencephalopathy (PML) who survive more than 1 year from onset of neurological symptoms (PML survivors). We reviewed clinical data including seizure history and MR imaging studies from PML survivors evaluated at our institution between 1997 and 2014. PML progressors who passed away within 1 year and patients with a history of seizures prior to PML diagnosis were excluded from the analysis. Of 64 PML survivors, 28 (44 %) developed seizures. The median time from the onset of PML symptoms to the first seizure was 5.4 months (range 0-159) and 64 % of patients with seizures had them within the first year. The presence of juxtacortical PML lesions was associated with a relative risk of seizures of 3.5 (p < 0.02; 95 % confidence interval (CI) 1.3-9.4) in multivariate analyses. Of all seizure types, 86 % were focal and 60 % most likely originated from the frontal lobes. Among seizure patients, 89 % required treatment, including one (54 %), two (25 %), or three (10.5 %) antiepileptic drugs. Seizures are a frequent complication in PML and can develop throughout the entire course of the disease. However, late onset seizures did not signify PML relapse. Seizures may require treatment with multiple antiepileptic medications and are a significant co-morbidity in PML.

Entities:  

Keywords:  Epilepsy; JC virus; Progressive multifocal leukoencephalopathy; Seizures; Survivors

Mesh:

Substances:

Year:  2015        PMID: 26676826      PMCID: PMC4937716          DOI: 10.1007/s13365-015-0414-3

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  40 in total

1.  Safe Treatment of Seizures in the Setting of HIV/AIDS.

Authors:  Omar Siddiqi; Gretchen L Birbeck
Journal:  Curr Treat Options Neurol       Date:  2013-08       Impact factor: 3.598

Review 2.  Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.

Authors:  David B Clifford; Andrea De Luca; Andrea DeLuca; David M Simpson; Gabriele Arendt; Gavin Giovannoni; Avindra Nath
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

Review 3.  PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section.

Authors:  Joseph R Berger; Allen J Aksamit; David B Clifford; Larry Davis; Igor J Koralnik; James J Sejvar; Russell Bartt; Eugene O Major; Avindra Nath
Journal:  Neurology       Date:  2013-04-09       Impact factor: 9.910

4.  Frequent infection of cortical neurons by JC virus in patients with progressive multifocal leukoencephalopathy.

Authors:  Christian Wüthrich; Igor J Koralnik
Journal:  J Neuropathol Exp Neurol       Date:  2012-01       Impact factor: 3.685

5.  Increased propensity to seizures after chronic cortical deafferentation in vivo.

Authors:  Dragos A Nita; Youssouf Cissé; Igor Timofeev; Mircea Steriade
Journal:  J Neurophysiol       Date:  2005-10-19       Impact factor: 2.714

6.  Progressive multifocal leukoencephalopathy after initiation of highly active antiretroviral therapy in a child with advanced human immunodeficiency virus infection: a case of immune reconstitution inflammatory syndrome.

Authors:  James J C Nuttall; Jo M Wilmshurst; Alvin P Ndondo; Jane Yeats; Craig Corcoran; Gregory D Hussey; Brian S Eley
Journal:  Pediatr Infect Dis J       Date:  2004-07       Impact factor: 2.129

7.  Metabolic profile of PML lesions in patients with and without IRIS: an observational study.

Authors:  Sarah Gheuens; Long Ngo; Xiaoen Wang; David C Alsop; Robert E Lenkinski; Igor J Koralnik
Journal:  Neurology       Date:  2012-08-22       Impact factor: 9.910

Review 8.  ILAE official report: a practical clinical definition of epilepsy.

Authors:  Robert S Fisher; Carlos Acevedo; Alexis Arzimanoglou; Alicia Bogacz; J Helen Cross; Christian E Elger; Jerome Engel; Lars Forsgren; Jacqueline A French; Mike Glynn; Dale C Hesdorffer; B I Lee; Gary W Mathern; Solomon L Moshé; Emilio Perucca; Ingrid E Scheffer; Torbjörn Tomson; Masako Watanabe; Samuel Wiebe
Journal:  Epilepsia       Date:  2014-04-14       Impact factor: 5.864

9.  Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV/AIDS patients in the current era.

Authors:  J L Casado; I Corral; J García; J Martinez-San Millán; E Navas; A Moreno; S Moreno
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-08-16       Impact factor: 3.267

10.  Virologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study.

Authors:  Jason F Okulicz; Greg A Grandits; Jacqueline A French; Jomy M George; David M Simpson; Gretchen L Birbeck; Anuradha Ganesan; Amy C Weintrob; Nancy Crum-Cianflone; Tahaniyat Lalani; Michael L Landrum
Journal:  AIDS Res Ther       Date:  2011-05-16       Impact factor: 2.250

View more
  5 in total

Review 1.  Progressive Multifocal Leukoencephalopathy in HIV-Uninfected Individuals.

Authors:  Deanna Saylor; Arun Venkatesan
Journal:  Curr Infect Dis Rep       Date:  2016-11       Impact factor: 3.725

2.  Progressive multifocal leukoencephalopathy in a patient post allo-HCT successfully treated with JC virus specific donor lymphocytes.

Authors:  M J Steinhardt; E Wiercinska; M Pham; G U Grigoleit; A Mazzoni; M Da-Via; X Zhou; K Meckel; K Nickel; J Duell; F C Krummenast; S Kraus; C Hopkinson; B Weissbrich; W Müllges; G Stoll; K M Kortüm; H Einsele; H Bonig; L Rasche
Journal:  J Transl Med       Date:  2020-04-21       Impact factor: 5.531

Review 3.  Fifty Years of JC Polyomavirus: A Brief Overview and Remaining Questions.

Authors:  Abigail L Atkinson; Walter J Atwood
Journal:  Viruses       Date:  2020-09-01       Impact factor: 5.048

Review 4.  Altered expression of microRNAs and B lymphocytes during Natalizumab therapy in multiple sclerosis.

Authors:  André Eduardo de Almeida Franzoi; Fernanda Subtil de Moraes Machado; Washigton Luiz Gomes de Medeiros Junior; Isabelle Pastor Bandeira; Wesley Nogueira Brandão; Marcus Vinicius Magno Gonçalves
Journal:  Heliyon       Date:  2021-06-09

Review 5.  Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease.

Authors:  Irene Cortese; Daniel S Reich; Avindra Nath
Journal:  Nat Rev Neurol       Date:  2020-11-20       Impact factor: 42.937

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.